Cargando…

Clinical case: Combined pulmonary fibrosis and emphysema with pulmonary hypertension – clinical management

BACKGROUND: Combined idiopathic pulmonary fibrosis (IPF) with pulmonary emphysema (CPFE) is a syndrome with a characteristic presentation of upper lobe emphysema and lower lobe fibrosis. While CPFE is a strong determinant of secondary precapillary pulmonary hypertension (PH), there is limited eviden...

Descripción completa

Detalles Bibliográficos
Autor principal: Cottin, Vincent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3633020/
https://www.ncbi.nlm.nih.gov/pubmed/23734851
http://dx.doi.org/10.1186/1756-0500-6-S1-S2
_version_ 1782266930490507264
author Cottin, Vincent
author_facet Cottin, Vincent
author_sort Cottin, Vincent
collection PubMed
description BACKGROUND: Combined idiopathic pulmonary fibrosis (IPF) with pulmonary emphysema (CPFE) is a syndrome with a characteristic presentation of upper lobe emphysema and lower lobe fibrosis. While CPFE is a strong determinant of secondary precapillary pulmonary hypertension (PH), there is limited evidence regarding the management of patients with CPFE and PH. CASE PRESENTATION: A 63 year-old male presented in 2006 with dyspnoea on exertion having quit smoking in 2003. Clinical examination, together with high resolution computed tomography, bronchoalveolar lavage, and echocardiographic assessments, suggested a diagnosis of CPFE without PH. In 2007, the patient received intravenous cyclophosphamide, N-acetylcysteine, and short-term anticoagulation treatment. Due to remission of acute exacerbations, the patient received triple combination therapy (prednisone, N-acetylcysteine and azathioprine). Upon progressive clinical worsening, long-term supplemental oxygen therapy was initiated in 2009. Repeated right heart catheterisation in 2011 confirmed PH and worsening pulmonary haemodynamics, and off-label ambrisentan therapy was initiated. Dyspnoea remained at follow-up, although significant haemodynamic improvement was observed. CONCLUSION: CFPE is a distinct but under-recognized and common syndrome with a characteristic presentation. Further studies are needed to ascertain the etiology, morbidity, and mortality of CPEF with or without PH, and to evaluate novel management options.
format Online
Article
Text
id pubmed-3633020
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-36330202013-04-25 Clinical case: Combined pulmonary fibrosis and emphysema with pulmonary hypertension – clinical management Cottin, Vincent BMC Res Notes Case Report BACKGROUND: Combined idiopathic pulmonary fibrosis (IPF) with pulmonary emphysema (CPFE) is a syndrome with a characteristic presentation of upper lobe emphysema and lower lobe fibrosis. While CPFE is a strong determinant of secondary precapillary pulmonary hypertension (PH), there is limited evidence regarding the management of patients with CPFE and PH. CASE PRESENTATION: A 63 year-old male presented in 2006 with dyspnoea on exertion having quit smoking in 2003. Clinical examination, together with high resolution computed tomography, bronchoalveolar lavage, and echocardiographic assessments, suggested a diagnosis of CPFE without PH. In 2007, the patient received intravenous cyclophosphamide, N-acetylcysteine, and short-term anticoagulation treatment. Due to remission of acute exacerbations, the patient received triple combination therapy (prednisone, N-acetylcysteine and azathioprine). Upon progressive clinical worsening, long-term supplemental oxygen therapy was initiated in 2009. Repeated right heart catheterisation in 2011 confirmed PH and worsening pulmonary haemodynamics, and off-label ambrisentan therapy was initiated. Dyspnoea remained at follow-up, although significant haemodynamic improvement was observed. CONCLUSION: CFPE is a distinct but under-recognized and common syndrome with a characteristic presentation. Further studies are needed to ascertain the etiology, morbidity, and mortality of CPEF with or without PH, and to evaluate novel management options. BioMed Central 2013-04-16 /pmc/articles/PMC3633020/ /pubmed/23734851 http://dx.doi.org/10.1186/1756-0500-6-S1-S2 Text en Copyright © 2013 Cottin; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Cottin, Vincent
Clinical case: Combined pulmonary fibrosis and emphysema with pulmonary hypertension – clinical management
title Clinical case: Combined pulmonary fibrosis and emphysema with pulmonary hypertension – clinical management
title_full Clinical case: Combined pulmonary fibrosis and emphysema with pulmonary hypertension – clinical management
title_fullStr Clinical case: Combined pulmonary fibrosis and emphysema with pulmonary hypertension – clinical management
title_full_unstemmed Clinical case: Combined pulmonary fibrosis and emphysema with pulmonary hypertension – clinical management
title_short Clinical case: Combined pulmonary fibrosis and emphysema with pulmonary hypertension – clinical management
title_sort clinical case: combined pulmonary fibrosis and emphysema with pulmonary hypertension – clinical management
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3633020/
https://www.ncbi.nlm.nih.gov/pubmed/23734851
http://dx.doi.org/10.1186/1756-0500-6-S1-S2
work_keys_str_mv AT cottinvincent clinicalcasecombinedpulmonaryfibrosisandemphysemawithpulmonaryhypertensionclinicalmanagement